Jul 7, 2022 8:00 am EDT Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
Jun 29, 2022 9:00 am EDT Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Jun 21, 2022 7:30 am EDT Opus Genetics Appoints Ben Yerxa, Ph.D., as Permanent Chief Executive Officer
Jun 8, 2022 8:00 am EDT Ocuphire to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics at Annual Macula Society Meeting
May 19, 2022 7:00 am EDT Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
May 13, 2022 8:00 am EDT Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
May 11, 2022 8:00 am EDT Ocuphire Pharma Announces Upcoming Presentations at the Retina World Congress, Clinical Trials at the Summit, and the H.C. Wainwright Global Investment Conference
May 4, 2022 4:05 pm EDT Opus Genetics Announces Promising New Data Highlighting Potential of AAV-based Gene Therapies for the Treatment of Rare Inherited Retinal Diseases
Apr 28, 2022 8:00 am EDT New Data on Potential of Opus AAV-based Gene Therapies for Rare Inherited Retinal Diseases to be Presented at Association for Research in Vision and Ophthalmology Annual Meeting 2022